Papa Vincenzo, Bodicoat Danielle H, Duarte Angela Arteaga, Dart John K G, De Francesco Maria
SIFI S.P.A., 36, Via Ercole Patti, 95025, Aci S. Antonio, Catania, Italy.
HEOR Value Hub, Brussels, Belgium.
Ophthalmol Ther. 2025 May 5. doi: 10.1007/s40123-025-01152-9.
Acanthamoeba keratitis (AK) was first identified in 1972 and the first patient cured with propamidine was reported in 1985. Treatment outcomes, before the advent of the first effective anti-amoebic treatment, were known to be poor and often required therapeutic keratoplasty (TK) but have not been evaluated in detail. Analysis of these outcomes has value for several reasons: it gives an historical perspective, describes the natural history of AK when the disease was minimally modified by the early treatments and provides a benchmark against which current treatments can be compared and how these have changed the therapeutic results.
We conducted a systematic literature review for the period 1970-1995 using PRISMA guidelines. The population of interest comprised patients with AK treated without products having established anti-amoebic activity against both trophozoites and cysts (biguanides or diamidines). The outcomes of interest were medical cure, TK and enucleation. Proportions and 95% confidence intervals were estimated.
Fifty-six case reports were eligible. Risk factors for AK were reported in 44/56 patients: contact lens wear in 30/44 (68.2%) and trauma in 14/44 (31.8%). The mean time from presentation to diagnosis was 7.3 weeks (standard deviation 9.3 weeks); 13/56 (23.2%) were diagnosed within 4 weeks. Topical treatments given to patients included corticosteroids (85.2%), antibiotics (85.2%), antivirals (72.2%) and antifungals (51.8%). Final visual acuity was ≥ 20/40 in 17/33 (51.5%) patients with no missing data. Medical cures were reported in 11/56 patients (19.6%), TK in 38/56 (67.9%), other surgery in 4/56 (7.1%) and enucleation in 3/56 (5.4%).
This study suggests that, before the availability of propamidine as the first effective treatment for AK, the clinical outcome of these patients was poor with only a few patients cured without surgery. These findings should be interpreted with caution because they rely on case reports and series that are subject to inherent bias.
棘阿米巴角膜炎(AK)于1972年首次被确认,1985年报道了首例使用丙脒治愈的患者。在首个有效的抗阿米巴治疗方法出现之前,已知治疗效果不佳,通常需要进行治疗性角膜移植术(TK),但尚未进行详细评估。分析这些结果具有多方面价值:它提供了一个历史视角,描述了在早期治疗对疾病影响最小的情况下AK的自然病程,并提供了一个基准,可据此比较当前治疗方法以及这些方法如何改变了治疗结果。
我们使用PRISMA指南对1970 - 1995年期间的文献进行了系统回顾。纳入的研究对象为接受过治疗但所用产品对滋养体和包囊均无既定抗阿米巴活性(双胍类或二脒类)的AK患者。关注的结果为药物治愈、TK和眼球摘除。估计了比例及95%置信区间。
56篇病例报告符合要求。44/56例患者报告了AK的危险因素:30/44(68.2%)为佩戴隐形眼镜,14/44(31.8%)为外伤。从出现症状到确诊的平均时间为7.3周(标准差9.3周);13/56(23.2%)在4周内确诊。给予患者的局部治疗包括皮质类固醇(85.2%)、抗生素(85.2%)、抗病毒药物(72.2%)和抗真菌药物(51.8%)。在17/33例无缺失数据的患者中,最终视力≥20/40。11/56例患者(19.6%)报告药物治愈,38/56例(67.9%)接受TK,4/56例(7.1%)接受其他手术,3/56例(5.4%)接受眼球摘除。
本研究表明,在丙脒作为AK的首个有效治疗方法出现之前,这些患者的临床结局较差,只有少数患者未经手术治愈。由于这些结果依赖于存在固有偏倚的病例报告和系列研究,因此应谨慎解读。